Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
Autor: | Brian R. Lane, Sabrina L. Noyes, Jacob Bruinius, Karl Dykema, Bin Tean Teh |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
medicine.drug_class
medicine.medical_treatment Cell Chromophobe Renal Cell Carcinoma Exceptional Response Case Report urologic and male genital diseases lcsh:RC870-923 Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine 030304 developmental biology 0303 health sciences Sunitinib business.industry General Medicine medicine.disease lcsh:Diseases of the genitourinary system. Urology Nephrectomy Vascular endothelial growth factor Clear cell renal cell carcinoma medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Cancer research business medicine.drug |
Zdroj: | Case Reports in Urology, Vol 2019 (2019) Case Reports in Urology |
ISSN: | 2090-6978 |
Popis: | There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data supporting its use in ChRCC is much more limited. A 56-year-old underwent palliative nephrectomy for locally-advanced ChRCC with sarcomatoid differentiation. Tumor gene expression profiling using Affymetrix HG-U133 Plus 2.0 GeneChip platform demonstrated significantly elevated VEGF-C expression compared to normal renal tissue n=12 and other types RCC n=158. Adjuvant sunitinib was used to treat his residual unresectable retroperitoneal lymph nodes. He demonstrated an exceptional response and underwent complete surgical resection four months later. He has been managed with TKIs for nearly nine years with only minimal disease progression. Additional studies exploring treatment options for patients with non-clear cell RCC are needed; in their absence, we would recommend TKIs for patients whose tumors bear a similar molecular profile. |
Databáze: | OpenAIRE |
Externí odkaz: |